These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8499130)

  • 1. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
    Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
    Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants.
    Woolley DE; Tetlow LC; Adlam DJ; Gearey D; Eden RD; Ward TH; Allen TD
    Exp Cell Res; 2002 Feb; 273(1):65-72. PubMed ID: 11795947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
    Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
    Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
    Rose WC; Basler GA
    In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
    Aird RE; Cummings J; Ritchie AA; Muir M; Morris RE; Chen H; Sadler PJ; Jodrell DI
    Br J Cancer; 2002 May; 86(10):1652-7. PubMed ID: 12085218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
    Sharp SY; Rowlands MG; Jarman M; Kelland LR
    Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
    Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
    Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.
    Schilder RJ; Hall L; Monks A; Handel LM; Fornace AJ; Ozols RF; Fojo AT; Hamilton TC
    Int J Cancer; 1990 Mar; 45(3):416-22. PubMed ID: 2307530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo.
    Caffrey PB; Frenkel GD
    Cancer Chemother Pharmacol; 2000; 46(1):74-8. PubMed ID: 10912582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
    Grosse PY; Bressolle F; Pinguet F
    Eur J Cancer; 1998 Jan; 34(1):168-74. PubMed ID: 9624253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.
    Zou W; Ma X; Yang H; Hua W; Chen B; Cai G
    Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
    Holford J; Beale PJ; Boxall FE; Sharp SY; Kelland LR
    Eur J Cancer; 2000 Oct; 36(15):1984-90. PubMed ID: 11000581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.
    Vikhanskaya F; Clerico L; Valenti M; Stanzione MS; Broggini M; Parodi S; Russo P
    Int J Cancer; 1997 Jul; 72(1):155-9. PubMed ID: 9212237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH; Li M; Deng S; Lu MS
    Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
    Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
    Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
    Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
    Molecules; 2017 May; 22(5):. PubMed ID: 28467373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
    Parekh H; Simpkins H
    Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.